The Europe Hemophilia Market would witness market growth of 5.7% CAGR during the forecast period (2023-2030).
The market is expanding as a result of a number of causes, including the rising prevalence of hemophilia, supportive government initiatives, and increased research and development for the creation of novel medicines. The growing target demographic, higher diagnostic rates, more people being diagnosed with the condition, and an increase in preventative therapy for hemophilia are all factors that support market expansion.
Due to the requirement for more clotting factors or a different type of clotting factor, treating bleeding episodes becomes incredibly challenging, and the expense of care for a person with an inhibitor can soar. Inhibitors frequently cause increased joint disease and other bleeding-related issues that lower the quality of life.
The European Commission has granted BioMarin's ROCTAVIANTM (valoctocogene roxaparvovec) gene therapy conditional marketing authorization for the management of severe hemophilia A. The therapy is specifically developed for adult patients that don't have a history of Factor VIII inhibitors and with no detectable antibodies to adeno-associated virus serotype 5 (AAV5). Additionally, the EC agreed with the European Medicines Agency's (EMA) proposal that Roctavian keep its orphan medicine status, allowing it a 10-year window of market exclusivity. Therefore, similar efforts and developments in the coming years will propel the market's growth.
The Germany market dominated the Europe Hemophilia Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,114.3 million by 2030. The UK market is exhibiting a CAGR of 4.8% during (2023 - 2030). Additionally, The France market would experience a CAGR of 6.5% during (2023 - 2030).
Based on Distribution Channel, the market is segmented into Specialty Pharmacies, and Hospital Pharmacies. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, and Others. Based on Treatment Type, the market is segmented into Prophylaxis, On-demand, and Cure. Based on Therapy, the market is segmented into Factor Replacement Therapy (Recombinant Factor Concentrates, and Plasma-derived Factor Concentrates), Desmopressin & Fibrin Sealants, and Gene Therapy & Monoclonal Antibodies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Hemophilia Market is Projected to reach USD 18.3 Billion by 2030, at a CAGR of 6.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB (Investor AB) and Sanofi S.A.
By Distribution Channel
By Type
By Treatment Type
By Therapy
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 